Variceal bleeding and portal hypertension: still a therapeutic challenge?
In the primary prevention of variceal hemorrhage, beta-blockers continue to be the first-line treatment. Newer nonselective beta-blockers with anti-alpha1-adrenergic activity, such as carvedilol, appear to have a better impact on reducing the hepatic venous pressure gradient than propranolol. The addition of isosorbide mononitrate appears to improve the effectiveness of beta-blockers in primary prophylaxis, but not that of somatostatin in the treatment of acute variceal hemorrhage. The use of vasoactive drugs alone in acute variceal bleeding has not proved to be more effective than endoscopic treatment. The advent of endoscopic variceal ligation (EVL) has strengthened the role of endoscopy in the management of bleeding esophageal varices. EVL has improved the results, particularly in terms of lowering the treatment-related morbidity, compared with endoscopic variceal sclerotherapy (EVS). However, the variceal recurrence rate after initial eradication with EVL is relatively high. In contrast to synchronous combined therapy with EVL plus EVS, metachronous combination of EVL and low-dose EVS may improve the results of EVL alone. For bleeding fundic varices, obliteration using cyanoacrylate is currently the treatment of choice. Endosonography (EUS) is coming into more widespread use in the assessment of variceal eradication and in further attempts to improve the results of endoscopic injection therapy. According to two meta-analysis studies, transjugular intrahepatic portosystemic shunt (TIPS) is not yet capable of replacing endoscopic treatment in the secondary prevention of variceal bleeding.
Seewald
S
S
Dept. of Interdisciplinary Endoscopy, University Hospital, Eppendorf, Hamburg, Germany.
Seitz
U
U
Yang
A M
AM
Soehendra
N
N
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D003487:Cyanoacrylates / Q000627:therapeutic use; D019160:Endosonography; D004932:Esophageal and Gastric Varices / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D006801:Humans; D006975:Hypertension, Portal / Q000628:therapy*; D008026:Ligation; D019168:Portasystemic Shunt, Transjugular Intrahepatic; D015911:Sclerotherapy; D014662:Vasoconstrictor Agents / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D003487:Cyanoacrylates; D014662:Vasoconstrictor Agents